Stroke prevention for non-valvular atrial fibrillation: how to make the right choice of directly acting oral anticoagulants?

Patients with atrial fibrillation have a high risk of developing stroke and death, which requires constant anticoagulant support. In this regard, the physician faces the difficult task of selecting the appropriate oral anticoagulant for patient with individual risk factors and comorbidities. Current...

Full description

Bibliographic Details
Main Authors: N. N. Kryukov, E. V. Sayutina, A. M. Osadchuk, M. A. Osadchuk
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2019-02-01
Series:Российский кардиологический журнал
Subjects:
Online Access:https://russjcardiol.elpub.ru/jour/article/view/2875
_version_ 1797856807296696320
author N. N. Kryukov
E. V. Sayutina
A. M. Osadchuk
M. A. Osadchuk
author_facet N. N. Kryukov
E. V. Sayutina
A. M. Osadchuk
M. A. Osadchuk
author_sort N. N. Kryukov
collection DOAJ
description Patients with atrial fibrillation have a high risk of developing stroke and death, which requires constant anticoagulant support. In this regard, the physician faces the difficult task of selecting the appropriate oral anticoagulant for patient with individual risk factors and comorbidities. Currently, three non-vitamin K antagonist oral anticoagulants or directly acting oral anticoagulants have been registered in the Russia, which in large randomized clinical trials (RCTs) were compared with warfarin in the prevention of stroke and systemic embolism. The present article analyzes the data of RCTs, postmarketing studies of oral anticoagulants, and presents groups of patients for whom these drugs are preferred. The choice of oral anticoagulants for the prevention of stroke in the following subgroups of patients with atrial fibrillation is discussed: patients with one stroke risk factor (CHA2DS2VASc1 in men or 2 in women), patients of different age groups, patients with concomitant coronary artery disease/acute coronary syndrome, a history of stroke, patients with chronic kidney disease, patients with a high risk of gastrointestinal bleeding, and a group of patients with concomitant arterial hypertension and chronic heart failure. We compared the efficacy and safety of oral non-vitamin K antagonist oral anticoagulants or directly acting oral anticoagulants with vitamin K antagonists in patients with non-valvular atrial fibrillation.
first_indexed 2024-04-09T20:46:25Z
format Article
id doaj.art-4f40c8035f9444d0b18b4419a7b455d4
institution Directory Open Access Journal
issn 1560-4071
2618-7620
language Russian
last_indexed 2024-04-09T20:46:25Z
publishDate 2019-02-01
publisher «FIRMA «SILICEA» LLC
record_format Article
series Российский кардиологический журнал
spelling doaj.art-4f40c8035f9444d0b18b4419a7b455d42023-03-29T21:23:32Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202019-02-01019410210.15829/1560-4071-2019-1-94-1022478Stroke prevention for non-valvular atrial fibrillation: how to make the right choice of directly acting oral anticoagulants?N. N. Kryukov0E. V. Sayutina1A. M. Osadchuk2M. A. Osadchuk3Samara State Medical UniversityI.M. Sechenov First Moscow State Medical UniversitySamara State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityPatients with atrial fibrillation have a high risk of developing stroke and death, which requires constant anticoagulant support. In this regard, the physician faces the difficult task of selecting the appropriate oral anticoagulant for patient with individual risk factors and comorbidities. Currently, three non-vitamin K antagonist oral anticoagulants or directly acting oral anticoagulants have been registered in the Russia, which in large randomized clinical trials (RCTs) were compared with warfarin in the prevention of stroke and systemic embolism. The present article analyzes the data of RCTs, postmarketing studies of oral anticoagulants, and presents groups of patients for whom these drugs are preferred. The choice of oral anticoagulants for the prevention of stroke in the following subgroups of patients with atrial fibrillation is discussed: patients with one stroke risk factor (CHA2DS2VASc1 in men or 2 in women), patients of different age groups, patients with concomitant coronary artery disease/acute coronary syndrome, a history of stroke, patients with chronic kidney disease, patients with a high risk of gastrointestinal bleeding, and a group of patients with concomitant arterial hypertension and chronic heart failure. We compared the efficacy and safety of oral non-vitamin K antagonist oral anticoagulants or directly acting oral anticoagulants with vitamin K antagonists in patients with non-valvular atrial fibrillation.https://russjcardiol.elpub.ru/jour/article/view/2875non-valvular atrial fibrillationanticoagulationstroke preventionnonvitamin k antagonist oral anticoagulants
spellingShingle N. N. Kryukov
E. V. Sayutina
A. M. Osadchuk
M. A. Osadchuk
Stroke prevention for non-valvular atrial fibrillation: how to make the right choice of directly acting oral anticoagulants?
Российский кардиологический журнал
non-valvular atrial fibrillation
anticoagulation
stroke prevention
nonvitamin k antagonist oral anticoagulants
title Stroke prevention for non-valvular atrial fibrillation: how to make the right choice of directly acting oral anticoagulants?
title_full Stroke prevention for non-valvular atrial fibrillation: how to make the right choice of directly acting oral anticoagulants?
title_fullStr Stroke prevention for non-valvular atrial fibrillation: how to make the right choice of directly acting oral anticoagulants?
title_full_unstemmed Stroke prevention for non-valvular atrial fibrillation: how to make the right choice of directly acting oral anticoagulants?
title_short Stroke prevention for non-valvular atrial fibrillation: how to make the right choice of directly acting oral anticoagulants?
title_sort stroke prevention for non valvular atrial fibrillation how to make the right choice of directly acting oral anticoagulants
topic non-valvular atrial fibrillation
anticoagulation
stroke prevention
nonvitamin k antagonist oral anticoagulants
url https://russjcardiol.elpub.ru/jour/article/view/2875
work_keys_str_mv AT nnkryukov strokepreventionfornonvalvularatrialfibrillationhowtomaketherightchoiceofdirectlyactingoralanticoagulants
AT evsayutina strokepreventionfornonvalvularatrialfibrillationhowtomaketherightchoiceofdirectlyactingoralanticoagulants
AT amosadchuk strokepreventionfornonvalvularatrialfibrillationhowtomaketherightchoiceofdirectlyactingoralanticoagulants
AT maosadchuk strokepreventionfornonvalvularatrialfibrillationhowtomaketherightchoiceofdirectlyactingoralanticoagulants